
ENERGENESIS — Investor Relations & Filings
Energenesis Biomedical Co., Ltd. specializes in the research and development of innovative pharmaceuticals through its proprietary ENERGI drug development platform. The company focuses on the activation of AMP-activated protein kinase (AMPK), a critical enzyme for cellular energy regulation, to develop therapeutic solutions for various diseases. Its core pipeline centers on small molecule purine compounds designed to modulate cellular energy metabolism. Operating with an intellectual property-driven strategy, the company manages the development cycle from early-stage drug discovery through clinical trial validation. Energenesis Biomedical aims to increase the value of its proprietary technologies for strategic out-licensing and collaboration with global pharmaceutical partners. In addition to drug development, the company offers specialized testing and analysis services and distributes research reagents.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 114年度股利金額(董事會決議) | 2026-05-22 | Chinese | |
| 115年第1季財務報告書 — 202601_6657_AI1.pdf | 2026-05-13 | Chinese | |
| 115年第1季海外子公司投資 | 2026-05-11 | Chinese | |
| 115年第1季權益變動表 | 2026-05-11 | Chinese | |
| 115年第1季現金流量表 | 2026-05-11 | Chinese | |
| 115年第1季綜合損益表 | 2026-05-11 | Chinese |
Browse filings by year
1 year| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46778242 | 114年度股利金額(董事會決議) | 2026-05-22 | Chinese | ||
| 46338951 | 115年第1季財務報告書 — 202601_6657_AI1.pdf | 2026-05-13 | Chinese | ||
| 45740777 | 115年第1季海外子公司投資 | 2026-05-11 | Chinese | ||
| 45746274 | 115年第1季權益變動表 | 2026-05-11 | Chinese | ||
| 45741609 | 115年第1季現金流量表 | 2026-05-11 | Chinese | ||
| 45741439 | 115年第1季綜合損益表 | 2026-05-11 | Chinese | ||
| 45741235 | 115年第1季資產負債表 | 2026-05-11 | Chinese | ||
| 39978408 | 114年第4季財務報告書 — 202502_6657_AIA.pdf | 2026-04-30 | English | ||
| 39871803 | 114年第4季財務報告書 — 202501_6657_AIA.pdf | 2026-04-30 | English | ||
| 39871783 | 114年第4季財務報告書 — 202501_6657_AI1.pdf | 2026-04-30 | Chinese | ||
| 39886223 | 114年第4季財務報告書 — 202504_6657_AIC.pdf | 2026-04-30 | English | ||
| 39886197 | 114年第4季財務報告書 — 202504_6657_AIA.pdf | 2026-04-30 | English | ||
| 39886176 | 114年第4季財務報告書 — 202504_6657_AI3.pdf | 2026-04-30 | Chinese | ||
| 39886119 | 114年第4季財務報告書 — 202504_6657_AI1.pdf | 2026-04-30 | Chinese | ||
| 39886095 | 114年第4季財務報告書 — 202503_6657_AIA.pdf | 2026-04-30 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Ginkgo Bioworks Holdings, Inc.
Operates a horizontal platform for cell programming and syn…
|
DNA | US | Professional, scientific and te… |
|
GRAIL, Inc.
A healthcare company developing blood tests for multi-cance…
|
GRAL | US | Professional, scientific and te… |
|
GT Biopharma, Inc.
Clinical-stage immuno-oncology company developing therapies…
|
GTBP | US | Professional, scientific and te… |
|
Guard Therapeutics International AB
Clinical-stage biotech developing therapies to prevent acut…
|
GUARD | SE | Professional, scientific and te… |
|
Gubra A/S
Biotech and CRO focused on peptide drugs for metabolic and …
|
GUBRA | DK | Professional, scientific and te… |
|
HALOZYME THERAPEUTICS, INC.
Biopharmaceutical firm licensing technology to convert IV d…
|
HALO | US | Professional, scientific and te… |
|
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.
Provides integrated R&D and manufacturing services for chem…
|
301096 | CN | Professional, scientific and te… |
|
Hangzhou Tigermed Consulting Co., Ltd.
Leading global Contract Research Organization (CRO) for ful…
|
3347 | HK | Professional, scientific and te… |
|
Hangzhou Tigermed Consulting Co.,Ltd.
Provides clinical research solutions for pharmaceutical, bi…
|
300347 | CN | Professional, scientific and te… |
|
HEALIOS K.K.
Clinical-stage biotech developing regenerative medicine and…
|
4593 | JP | Professional, scientific and te… |
ENERGENESIS via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52601/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52601 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52601 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52601 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52601}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ENERGENESIS (id: 52601)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.